

December 2019

Osteoarthritis (OA)



- We presented new data on lorecivivint, our OA drug currently in pivotal Phase 3 clinical trials, at the American College of Rheumatology (ACR) Annual Meeting; a link to an interview with our Chief Medical Officer, Dr. Yusuf Yazici, can be found [here](#)
- We completed enrollment of our Phase 2/3, multiple-injection safety and tolerability study of lorecivivint

Oncology (ONC)



- Our SM08502 oncology program's novel mechanism of action for anti-tumor activity and potential treatment of cancer (solid tumors), has been published in a peer-reviewed article in the *Cancer Letters* journal, which can be found [here](#)
- We initiated a Phase 1 clinical trial for SM09419, our second oncology compound for potential treatment of lymphomas and leukemias

Corporate News



- We have moved into our new office and lab facility, which will accommodate our ongoing growth